About Sentiss(Formerly known as Promed Exports Private Limited)

Incorporated in 1990, Sentiss is committed to providing the best quality pharmaceutical products primarily in the Ophthalmic, ENT and Inhalation segments. Over the past 25 years, by exhibiting commitment and showcasing our winning culture, Sentiss has evolved tremendously and is recognized as the third best Ophthalmic Company (IMS 2015) in Russia. Sentiss’ footprint on the world map is a testimony to its quality philosophy and practice of product differentiation. Sentiss strives to be a global leader in its core segment and continues to expand its operations in Russia, CIS, Europe, USA and Indian markets.
Sentiss has a quality workforce of 700+ people across multiple geographies. Sentiss is recognized as one of the Top 100 Great Places to Work in India in 2015. Since its inception in 1990, we have been continuously evolving and has crossed several milestones during this journey. Sentiss Research Centre (SRC) filed 50 patent applications out of which 9 patents have been granted till end of Q2 2016.

  • Established as Promed Exports Private Limited
  • Initiated operations in Russia and launched branded ophthalmic products
  • Established Sentiss Research Centre in Gurgaon (India)
  • Entered the Ukraine market
  • Commenced production at Sentiss manufacturing facility at Nalagarh (India)
  • Sentiss was ranked #3 in 2008 and subsequently #2 in 2009 by IMS (Sales Data) in Russian generic ophthalmic market
  • Received ISO 13485:2003 and WHO-GMP approvals
  • Accredited with financial rating of BBB+ by S&P India (Crisil)
  • First product registered in EU
  • Foundation of Scientific Advisory Board for Accommodation and Refraction (SABAR) in Russia
  • 10 Patent applications filed. 1 Eurasian patent granted on April 30, 2010
  • Filed four ANDA’s with the US FDA
  • Received TGA, Australia approval for manufacturing facility
  • Launched Indian business division—Provis
  • Dispatched first US shipment
  • Manufacturing Facility at Nalagarh received ISO 14001 and OHSAS 18001 certification
  • 2 patent applications filed. 1 Eurasian patent granted on Feb 28, 2011
  • Filed three ANDA’s with US FDA
  • Accredited with financial rating of A-/stable by S&P, India (Crisil)
  • Release and publication of Guidelines for Accommodation disorders by Scientific Advisory Board for Accommodation and Refraction (SABAR)
  • 2 Eurasian patents granted on July 30, 2012 and Nov 30, 2012 respectively
  • Re-branded the company from Promed to Sentiss
  • Filed two ANDA’s with the US FDA
  • Opened subsidiaries in Switzerland, Russia and the USA
  • Reaffirmed with financial rating of A2+ and A-/stable by S&P, India (Crisil) in short term and long term respectively
  • 8 patent applications filed. 1 European patent granted on Aug 14, 2013
  • Most Innovative Company of the Year Award: Sentiss was declared the “Most Innovative Company of the Year” in the mid sized emerging company category at the Yes Bank Best Emerging Companies awards.
  • EU GMP and WHO GMP Approvals: Sentiss received manufacturing facility regulatory approvals in 2014
  • 4 patent applications filed. 1 United States patent granted on Mar 25, 2014